Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Placebo-Controlled, Randomized, Single-Blind Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease.

Next Previous
X
Search
Trial Profile

A Phase 2a, Placebo-Controlled, Randomized, Single-Blind Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GCS 100 (Primary)
  • Indications Renal failure
  • Focus Therapeutic Use
  • Sponsors La Jolla Pharmaceutical Company

    • Most Recent Events

    • 12 Nov 2014 Results were presented at the American Society of Nephrology's (ASN) Kidney Week Annual Meeting according to a La Jolla Pharmaceutical Company media release reporting the results.
    • 12 Nov 2014 Primary endpoint (Change in eGFR from baseline relative to placebo after administration of GCS-100 for 8 weeks in patients with CKD) has been met for 1.5 mg/m2 dose but not for 30 mg/m2 dose according to a La Jolla media release.
    • 23 Oct 2014 Status changed from active, no longer recruiting to completed, according to a La Jolla Pharmaceutical Company media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top